Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Hypericin sodium - Soligenix

Next Previous
X
Search
Drug Profile

Hypericin sodium - Soligenix

Alternative Names: HyBryte; Hypericin - Soligenix; SGX-301; SGX-302; Synthetic hypericin - Soligenix; VIMRxyn

Latest Information Update: 12 Jul 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator New York University; Weizmann Institute of Science
  • Developer Soligenix
  • Class Anthraquinones; Anti-inflammatories; Antidepressants; Antineoplastics; Antipsoriatics; Antivirals; Cytostatics; Perylenes; Polycyclic compounds; Radiation-sensitising agents; Skin disorder therapies; Small molecules
  • Mechanism of Action Cell death stimulants; HSP90 heat-shock protein inhibitors; Immunosuppressants; Photosensitisers; Protein kinase C inhibitors; Singlet oxygen stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cutaneous T-cell lymphoma; T-cell lymphoma; Glioblastoma
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Cutaneous T-cell lymphoma
  • Phase II Mycosis fungoides; Psoriasis
  • Discontinued Glioma; Hepatitis C; HIV infections; Hyperhidrosis; Kaposi's sarcoma

Most Recent Events

  • 09 Jul 2024 Efficacy and adverse events data from a phase II trial in Mycosis fungoides released by Soligenix
  • 03 Apr 2024 Soligenix plans a phase III FLASH-2 trial for Cutaneous T-cell lymphoma (Early stage disease) in USA, Europe (Topical) (NCT06470451)
  • 03 Apr 2024 Soligenix receives agreement on the design of a second confirmatory phase III FLASH-2 trial from European Medicines Agency

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top